As of Feb 11
| -0.24 / -0.07%|
The 20 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals have a median target of 597.00, with a high estimate of 676.00 and a low estimate of 400.00. The median estimate represents a +62.56% increase from the last price of 367.24.
The current consensus among 24 polled investment analysts is to Buy stock in Regeneron Pharmaceuticals. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.